Document Detail


A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.
MedLine Citation:
PMID:  20635083     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Screening a phage-display single-chain antibody library for binding to the breast cancer cell line PM-1 an antibody, scFv173, recognising activated leukocyte cell adhesion molecule (ALCAM, CD166) was isolated and its binding profile was characterized. Positive ALCAM immunohistochemical staining of frozen human tumour sections was observed. No ALCAM staining was observed in the majority of tested normal human tissues (nine of ten). Flow cytometry analyses revealed binding to 22 of 26 cancer cell lines of various origins and no binding to normal blood and bone marrow cells. Antibody binding inhibited invasion of the breast cancer cell line MDA-MB-231 by 50% in an in vitro Matrigel-coated membrane invasion assay. Reduced growth of tumours in nude mice was observed in an in vivo model in which the mice were injected subcutaneously with colorectal carcinoma HCT 116 cells and treated with scFv173 when compared to control. In summary, we have characterized a novel fully human scFv antibody recognising ALCAM on cancer cells and in tumour tissues that reduces cancer cell invasion and tumour growth in accordance with the hypothesised role for ALCAM in cell growth and migration control.
Authors:
Merete Thune Wiiger; Hege B Gehrken; Øystein Fodstad; Gunhild M Maelandsmo; Yvonne Andersson
Related Documents :
20106643 - Selective induction of apoptosis in glioma tumour cells by a gynostemma pentaphyllum ex...
80213 - The distribution of feulgen stained nuclei in the periphery of human head and neck tumo...
9214723 - Effects of some saturated n-alkanes on the survival of escherichia coli resting cells i...
Publication Detail:
Type:  In Vitro; Journal Article     Date:  2010-07-16
Journal Detail:
Title:  Cancer immunology, immunotherapy : CII     Volume:  59     ISSN:  1432-0851     ISO Abbreviation:  Cancer Immunol. Immunother.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-08-30     Completed Date:  2010-09-21     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  8605732     Medline TA:  Cancer Immunol Immunother     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1665-74     Citation Subset:  IM    
Affiliation:
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. merete.thune.wiiger@rr-research.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Activated-Leukocyte Cell Adhesion Molecule / immunology*
Animals
Colorectal Neoplasms / immunology,  pathology,  prevention & control*
Humans
Immunoglobulin Fragments / therapeutic use*
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Invasiveness
Recombinant Proteins / genetics,  immunology,  metabolism*
Single-Chain Antibodies / therapeutic use*
Survival Rate
Chemical
Reg. No./Substance:
0/Activated-Leukocyte Cell Adhesion Molecule; 0/Immunoglobulin Fragments; 0/Recombinant Proteins; 0/Single-Chain Antibodies
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Characterization of alcohol dehydrogenase 1 of the thermotolerant methylotrophic yeast Hansenula pol...
Next Document:  Hypoparathyroidism after total parathyroidectomy plus subcutaneous autotransplantation for secondary...